Luye Pharma Group Ltd. (HKG:2186)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
2.470
+0.010 (0.41%)
Mar 10, 2026, 3:59 PM HKT
3.78%
Market Cap 9.83B
Revenue (ttm) 6.76B
Net Income (ttm) 434.95M
Shares Out 3.99B
EPS (ttm) 0.12
PE Ratio 21.28
Forward PE 11.96
Dividend n/a
Ex-Dividend Date n/a
Volume 12,203,000
Average Volume 16,200,175
Open 2.490
Previous Close 2.460
Day's Range 2.440 - 2.520
52-Week Range 1.670 - 4.490
Beta 1.00
RSI 35.53
Earnings Date Mar 27, 2026

About Luye Pharma Group

Luye Pharma Group Ltd., together with its subsidiaries, develops, produces, markets, and sells pharmaceutical products in the People’s Republic of China, the United States, Europe, and internationally. The company offers Lipusu for ovarian cancer and carcinoma of ovary; CMNa, a chemical sensitizer for cancer radiotherapy; Boyounuo, an injection for the treatment of various types of cancers; and Xuezhikang, a lipid-regulating drug for the treatment of hypercholesterolaemia. It also provides Maitongna for cerebral edema swelling by trauma or surg... [Read more]

Sector Healthcare
Founded 1994
Employees 5,115
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2186
Full Company Profile

Financial Performance

In 2024, Luye Pharma Group's revenue was 6.06 billion, a decrease of -1.33% compared to the previous year's 6.14 billion. Earnings were 471.89 million, a decrease of -11.40%.

Financial numbers in CNY Financial Statements

News

There is no news available yet.